Key points are not available for this paper at this time.
We present feasibility, acceptability, and efficacy of 3 delivery arms of a new scalable, digital treatment we designed to target DD in families of school-agers with T1D. We randomized 34 families (mean child age= 10u+/u1.4 years; 53% male, 85% White, mean HbA1c= 7.24u+/u0.71%) to 1 of 3 delivery arms differing only by number of telehealth visits: 0 visits= self-guided (SG), 3 visits= enhanced self-guided (ESG), or 8 visits= video visits (VV). All families had 24x7 access to digital treatment materials via their hospital’s patient portal app for 10 weeks. We recorded telehealth visit attendance (ESG Novo Nordisk A/S. Other Relationship; American Diabetes Association. Research Support; Provention Bio, Inc., Sanofi-Aventis U.S., Beta Bionics. Stock/Shareholder; KiHealth Board Member. L.A. Fox: Advisory Panel; Ki Health. Research Support; Dexcom, Inc. M.A. Clements: Research Support; Abbott. Consultant; Glooko, Inc. Research Support; Dexcom, Inc. Funding National Institutes of Health (R01 DK127493)
PATTON et al. (Fri,) studied this question.